BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 21983957)

  • 1. Namibia becomes first country in Africa to launch dabigatran etexilate for atrial fibrillation.
    Wagenaar P
    Cardiovasc J Afr; 2011; 22(5):283. PubMed ID: 21983957
    [No Abstract]   [Full Text] [Related]  

  • 2. Dabigatran etexilate (Pradaxa) for the treatment of atrial fibrillation.
    Belavic JM
    Nurse Pract; 2011 Sep; 36(9):6-7. PubMed ID: 21857210
    [No Abstract]   [Full Text] [Related]  

  • 3. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice.
    Huisman MV; Lip GY; Diener HC; Brueckmann M; van Ryn J; Clemens A
    Thromb Haemost; 2012 May; 107(5):838-47. PubMed ID: 22318514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate.
    Roskell NS; Lip GY; Noack H; Clemens A; Plumb JM
    Thromb Haemost; 2010 Dec; 104(6):1106-15. PubMed ID: 20967400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: NICE guidance.
    Ahmad Y; Lip GY
    Heart; 2012 Oct; 98(19):1404-6. PubMed ID: 22698856
    [No Abstract]   [Full Text] [Related]  

  • 6. [Stroke prevention in atrial fibrillation. Marcumar alternative in sight].
    Einecke D
    MMW Fortschr Med; 2009 Sep; 151(38):12-4. PubMed ID: 19831172
    [No Abstract]   [Full Text] [Related]  

  • 7. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial.
    Paikin JS; Haroun MJ; Eikelboom JW
    Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):279-86. PubMed ID: 21438804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dabigatran versus warfarin for patients with non-valvular atrial fibrillation: is the patient the winner?
    Grave S
    Aust Nurs J; 2011 Dec-2012 Jan; 19(6):30-3. PubMed ID: 22329103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dabigatran etexilate in people with atrial fibrillation.
    Raju NC; Hankey GJ
    BMJ; 2010 Jul; 341():c3784. PubMed ID: 20671015
    [No Abstract]   [Full Text] [Related]  

  • 11. Dabigatran in clinical practice.
    Nagarakanti R; Ellis CR
    Clin Ther; 2012 Oct; 34(10):2051-60. PubMed ID: 23031622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA committee unanimously recommends approval of dabigatran etexilate for stroke prevention in atrial fibrillation.
    Aalbers J; Bryer A; Klug E
    Cardiovasc J Afr; 2010; 21(6):341. PubMed ID: 21135985
    [No Abstract]   [Full Text] [Related]  

  • 13. Dabigatran for stroke prevention in all patients with atrial fibrillation?
    Hunchuck JE; Lake JD
    Pharmacotherapy; 2011 Aug; 31(8):725-8. PubMed ID: 21923597
    [No Abstract]   [Full Text] [Related]  

  • 14. Atrial fibrillation: A promising new anticoagulant for stroke prevention.
    Spinler SA
    Nat Rev Cardiol; 2010 Jan; 7(1):10-1. PubMed ID: 20019756
    [No Abstract]   [Full Text] [Related]  

  • 15. Rash associated with dabigatran etexilate.
    To K; Reynolds C; Spinler SA
    Pharmacotherapy; 2013 Mar; 33(3):e23-7. PubMed ID: 23400964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should dabigatran replace warfarin for stroke prevention in AF?
    Drug Ther Bull; 2011 Oct; 49(10):114-7. PubMed ID: 21994438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patients.
    Ellis CR; Kaiser DW
    Vasc Health Risk Manag; 2013; 9():341-52. PubMed ID: 23874100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. At last, a RE-LYable alternative to warfarin for atrial fibrillation.
    Hankey GJ
    Int J Stroke; 2009 Dec; 4(6):454-5. PubMed ID: 19930055
    [No Abstract]   [Full Text] [Related]  

  • 19. Initial experience with dabigatran etexilate at Auckland City Hospital.
    Bell S; Nand J; Spriggs D; Young L; Dawes M
    N Z Med J; 2012 Feb; 125(1349):105-7. PubMed ID: 22327149
    [No Abstract]   [Full Text] [Related]  

  • 20. Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation.
    Siddiqui FM; Qureshi AI
    Expert Opin Pharmacother; 2010 Jun; 11(8):1403-11. PubMed ID: 20446854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.